Table 3.
Volumetric data of PVE/HVE in all published series
| Author | FLR (preintervention) PVE/HVE | Time between embolization and imaging (days) | FLR (postintervention) PVE/HVE | Percent hypertrophy | Degree of hypertrophy | KGR |
|---|---|---|---|---|---|---|
| Guiu et al. [15] |
28.2% FLR (range 22.4–33.3) |
23 (range 13–30) |
40.9% FLR (range 33.6–59.3) |
n.r. | 12.7% FLR | 4.2% sFLR/week |
| Guiu et al. [25] |
20.8% sFLR (SD ±5.1) |
7 14 21 |
31.8% sFLR (SD ± 8.2) 33.4% sFLR (SD ± 7.2) 33.4% sFLR (SD ± 6.7) |
53.4%ε 62.5%ε 63.3%ε |
n.r. |
7.6 cc/day (SD ± 2.4)# 0.9 cc/day (SD ± 0.9)# 0.1 cc/day (SD ± 1.3)# |
| Le Roy et al. [26] |
21% FLR (IQR 14–37) |
22 (IQR 19–28) |
30% FLR (IQR 25–47) |
52.6% (absolute FLR) (IQR18–188) |
n.r. | unclear |
| Hocquelet et al. [27] |
30.5% FLR (IQR 23–35.5) |
23.5 (IQR 15–29) |
42.3% FLR (IQR 34–47) /58% sFLR (IQR 54–71) |
67% FLR (IQR 29–123) |
n.r. | n.r. |
| Panaro et al. [28] |
31.2% FLR (SD ±6.5) |
21 |
40.8% FLR (SD ± 7.9%) |
n.r. | n.r. | 16 cc/day (SD ±7) |
| Kobayashi et al. [29] |
25% sFLR (IQR 23–31) |
22 (IQR 17–30) |
36% sFLR (IQR 31–40) |
35% FLR (IQR 23–54) |
8.9% FLR (IQR 6.7–12.8) |
2.9% FLR/week (IQR 1.9–4.3) |
| Le Roy et al. [30] |
394 cc (CI 262–478) |
26 |
527 cc (CI 416–662) |
51.2% (SD ± 41.7) |
10% (SD ± 6) |
unclear |
| Laurent et al. [31] |
22.91% FLR (range 16.55–32.15) |
31 (± 2) |
39.89% FLR (range 30.64–52.92) |
61.18% FLR (range 18–201) |
n.r. | n.r. |
n.r. not reported cc cubic centimeter CI confidence interval FLR future liver remnant IQR interquartile range KGR kinetic growth rate SD standard deviation sFLR standardized future liver remnant
εPercent hypertrophy (absolute FLR volume) from baseline
#KGR (in cc per day) from baseline